Weleader Biomedical Co (ROCO:7713) Piotroski F-Score: 6 (As of Jul. 02, 2026) — 25% Below Median


ROCO:7713 Weleader Biomedical Co Ltd ROCO:7713
47 GF Score
Price NT$70.10
! 5 Warning Signs
View Full Analysis

What is Weleader Biomedical Co Piotroski F-Score?

Weleader Biomedical Co ROCO:7713 -1.54% 47 Piotroski F-Score is 6 as of Jul. 02, 2026, which is 25% below its 10-year median of 8.00. GuruFocus rates ROCO:7713 with a GF Score™ of 47/100. The stock has 5 warning signs investors should review. Among 806 Medical Devices & Instruments companies, Weleader Biomedical Co ranks better than 81.14% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Weleader Biomedical Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Weleader Biomedical Co's Piotroski F-Score or its related term are showing as below:

ROCO:7713' s Piotroski F-Score Range Over the Past 10 Years
Min: 6   Med: 8   Max: 9
Current: 6

During the past 6 years, the highest Piotroski F-Score of Weleader Biomedical Co was 9. The lowest was 6. And the median was 8.

Weleader Biomedical Co  (ROCO:7713) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Weleader Biomedical Co Piotroski F-Score Related Terms


Weleader Biomedical Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Weleader Biomedical Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Weleader Biomedical Co Piotroski F-Score Chart

Weleader Biomedical Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial N/A N/A N/A 9.00 6.00

Weleader Biomedical Co Quarterly Data
Dec20 Dec21 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.00 N/A 5.00 N/A 6.00

ROCO:7713 vs ABT, SYK, MDT: Piotroski F-Score Comparison

For the Medical Devices subindustry, Weleader Biomedical Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Weleader Biomedical Co Piotroski F-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Weleader Biomedical Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Weleader Biomedical Co's Piotroski F-Score falls into.


ROCO:7713
47GF Score
Weleader Biomedical Co Ltd ROCO:7713
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Net Income was 40.978 + 50.011 + 59.827 + 57.739 = NT$209 Mil.
Cash Flow from Operations was 71.979 + 60.715 + 47.484 + 133.117 = NT$313 Mil.
Revenue was 245.133 + 273.086 + 295.891 + 295.19 = NT$1,109 Mil.
Gross Profit was 77.993 + 88.415 + 102.29 + 102.268 = NT$371 Mil.
Average Total Assets from the begining of this year (Dec24)
to the end of this year (Dec25) was
(1998.062 + 2195.036 + 2123.907 + 2323.12 + 2448.985) / 5 = NT$2217.822 Mil.
Total Assets at the begining of this year (Dec24) was NT$1,998 Mil.
Long-Term Debt & Capital Lease Obligation was NT$757 Mil.
Total Current Assets was NT$780 Mil.
Total Current Liabilities was NT$432 Mil.
Net Income was 44.232 + 41.713 + 44.063 + 40.204 = NT$170 Mil.

Revenue was 235.052 + 252.622 + 255.54 + 247.911 = NT$991 Mil.
Gross Profit was 79.645 + 79.456 + 81.025 + 76.198 = NT$316 Mil.
Average Total Assets from the begining of last year (Dec23)
to the end of last year (Dec24) was
(1727.56 + 0 + 1984.417 + 1968.904 + 1998.062) / 5 = NT$1919.73575 Mil.
Total Assets at the begining of last year (Dec23) was NT$1,728 Mil.
Long-Term Debt & Capital Lease Obligation was NT$618 Mil.
Total Current Assets was NT$591 Mil.
Total Current Liabilities was NT$469 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Weleader Biomedical Co's current Net Income (TTM) was 209. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Weleader Biomedical Co's current Cash Flow from Operations (TTM) was 313. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec24)
=208.555/1998.062
=0.10437864

ROA (Last Year)=Net Income/Total Assets (Dec23)
=170.212/1727.56
=0.0985274

Weleader Biomedical Co's return on assets of this year was 0.10437864. Weleader Biomedical Co's return on assets of last year was 0.0985274. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Weleader Biomedical Co's current Net Income (TTM) was 209. Weleader Biomedical Co's current Cash Flow from Operations (TTM) was 313. ==> 313 > 209 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec24 to Dec25
=756.563/2217.822
=0.34112882

Gearing (Last Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=617.901/1919.73575
=0.32186774

Weleader Biomedical Co's gearing of this year was 0.34112882. Weleader Biomedical Co's gearing of last year was 0.32186774. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec25)=Total Current Assets/Total Current Liabilities
=780.386/432.302
=1.80518711

Current Ratio (Last Year: Dec24)=Total Current Assets/Total Current Liabilities
=591.319/469.005
=1.26079466

Weleader Biomedical Co's current ratio of this year was 1.80518711. Weleader Biomedical Co's current ratio of last year was 1.26079466. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Weleader Biomedical Co's number of shares in issue this year was 51.171. Weleader Biomedical Co's number of shares in issue last year was 41.732. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=370.966/1109.3
=0.3344145

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=316.324/991.125
=0.31915651

Weleader Biomedical Co's gross margin of this year was 0.3344145. Weleader Biomedical Co's gross margin of last year was 0.31915651. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec24)
=1109.3/1998.062
=0.55518798

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec23)
=991.125/1727.56
=0.57371379

Weleader Biomedical Co's asset turnover of this year was 0.55518798. Weleader Biomedical Co's asset turnover of last year was 0.57371379. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+0+1+0+1+0
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Weleader Biomedical Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 6 mean?
Weleader Biomedical Co (ROCO:7713) has a Piotroski F-Score of 6 as of Jul. 02, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Weleader Biomedical Co and its competitors. This is 25% below median its historical median of 8.00. Over the past decade, Weleader Biomedical Co's Piotroski F-Score has ranged from 6.00 to 9.00. According to the industry distribution chart, Weleader Biomedical Co ranks #152 out of 806 companies in the Medical Devices & Instruments industry, placing it in the top 18.9%.
Is Weleader Biomedical Co's Piotroski F-Score too high?
Weleader Biomedical Co's current Piotroski F-Score of 6 is 25% below median its 10-year median of 8.00. Over the past 10 years, this metric has ranged from a low of 6.00 to a high of 9.00. The Medical Devices & Instruments industry median Piotroski F-Score is 5.00. Weleader Biomedical Co's value of 6 is 20% above this industry median. Based on the distribution chart, Weleader Biomedical Co ranks #152 out of 806 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Weleader Biomedical Co has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Weleader Biomedical Co's Piotroski F-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Weleader Biomedical Co ranks #152 out of 806 companies for Piotroski F-Score. This places Weleader Biomedical Co in the top 19% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Weleader Biomedical Co's value of 6 is 20% above this benchmark. Historically, Weleader Biomedical Co's own Piotroski F-Score has ranged from 6.00 to 9.00 over the past decade. While the company's 10-year median is 8.00 vs. the industry median of 5.00, Weleader Biomedical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Devices & Instruments company?
The median Piotroski F-Score among Medical Devices & Instruments companies is 5.00, based on 806 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Weleader Biomedical Co's current Piotroski F-Score of 6 is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Weleader Biomedical Co and its competitors. For the Medical Devices & Instruments industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Weleader Biomedical Co's current Piotroski F-Score is 6, which is 25% below median its own 10-year median of 8.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Weleader Biomedical Co stock overvalued right now?
Weleader Biomedical Co (ROCO:7713) has a current Piotroski F-Score of 6. The current Piotroski F-Score is 6, which is 25% below median its 10-year median of 8.00 and 20% above the Medical Devices & Instruments industry median of 5.00. Weleader Biomedical Co's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Weleader Biomedical Co (ROCO:7713), the current Piotroski F-Score is 6 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Weleader Biomedical Co Business Description

Address No. 80, Minzu 1st Road, 19th Floor - 1 & 2, Sanmin District, Kaohsiung, TWN
Weleader Biomedical Co Ltd is mainly engages in the sales of medical testing reagents and medical devices; and the leasing of testing instruments. The reportable segments of the Group are: The Company, which includes sale of testing reagents, and provision of testing instruments and services; and Health Leader, which includes sale of dietary supplements and testing reagents, and provision of information and professional services. It derives majority revenue from the Company segment. Geographically, the company operates and generates revenue from Taiwan.
47GF Score

Get the complete analysis for ROCO:7713

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$70.10
Price